Literature DB >> 32931143

Analysis on risk factors of lung cancer complicated with pulmonary embolism.

Yong-Qi Cui1, Xiao-Ming Tan1, Bin Liu1, Yu Zheng1, Li-Yan Zhang1, Zeng-Ai Chen2, Xue-Ling Wu1.   

Abstract

INTRODUCTION: Pulmonary embolism (PE) is a potentially fatal complication and its morbidity together with fatalness will further increase when in patients with malignant tumors. Fast and accurate early diagnosis of PE thus seems considerably important.
OBJECTIVE: To explore the risk factors of lung cancer complicated with PE.
MATERIALS AND METHODS: A retrospective cohort study consisted of 40 lung cancer patients with PE (PE group) and 60 lung cancer patients without PE (non-PE group) were analyzed.
RESULTS: The white blood cell (WBC) count, D-dimer and low-density lipoprotein (LDL) were higher in PE group than those in non-PE group (P < 0.05), whereas the arterial partial pressure of oxygen (PaO2 ) in PE group was lower than that in non-PE group (P < 0.05). Carcinoembryonic antigen (CEA) level between two groups also exhibited statistical difference (P < 0.05). Those lung adenocarcinoma patients with stages III and IV tumor, coupled with deep venous thrombosis (DVT), having experienced bevacizumab treatment or platinum-based chemotherapy more likely suffered from PE (P < 0.05). The multivariate analysis revealed that high D-dimer, chemotherapy, DVT, stages III to IV, adenocarcinoma were independent risk factors associated with PE (P < 0.05). The overall survival time of patients in case group was significantly shorter than that in the control group with a median survival duration being 10.5 months (95%CI, 8.95-12.05) and 16.8 months (95%CI, 14.62-18.98), respectively, (P < 0.01).
CONCLUSIONS: High D-dimer, chemotherapy, DVT, stages III to IV and adenocarcinoma might have a positive correlation with PE, meanwhile, PE always predicted a poor prognosis in lung cancer patients.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  lung cancer; pulmonary embolism; retrospective study; risk factors

Year:  2020        PMID: 32931143     DOI: 10.1111/crj.13270

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  3 in total

1.  Risk Assessment of Death of Tumor-Related PTE by CAR Combined with DD Detection.

Authors:  Xinran Li; Jiamin Zheng; Ye Lu; Xiangtao Pan
Journal:  Vasc Health Risk Manag       Date:  2022-06-22

2.  Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database.

Authors:  Yuko Kanbayashi; Mayako Uchida; Misui Kashiwagi; Hitomi Akiba; Tadashi Shimizu
Journal:  Sci Rep       Date:  2022-09-16       Impact factor: 4.996

Review 3.  Are cardiovascular comorbidities always associated with a worse prognosis in patients with lung cancer?

Authors:  Sabina Mędrek; Sebastian Szmit
Journal:  Front Cardiovasc Med       Date:  2022-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.